Jason Lobel
About Jason Lobel
Jason Lobel was appointed to IMAC Holdings, Inc.’s (BACK) Board of Directors on June 2, 2025. He is a serial entrepreneur with a background in AI/analytics and healthcare data, and holds a BBA in Finance, Investment and Banking from the University of Wisconsin–Madison . The company disclosed no family relationships and no transactions requiring Item 404(a) related-party disclosure in connection with his appointment . Age is not disclosed in filings; tenure on the board began in June 2025 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| SwiftIQ (venture-backed AI & analytics platform) | Co-Founder & CEO | Previously (dates not disclosed) | Built real-time consumer transaction analytics; scaled across convenience retail and CPG ecosystems . |
| PDI Software | Vice President of Sales Growth | Post-acquisition of SwiftIQ (dates not disclosed) | Led data monetization and digital transformation initiatives . |
| Duff & Phelps (now Kroll) | Director, Investment Banking | Earlier in career (dates not disclosed) | Corporate finance experience; deal execution . |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| GenomicMD (precision health diagnostics) | Co-Founder & CEO | Current (as of appointment) | Genomic analysis for early detection/prevention across cancers, cardiovascular disease, diabetes, etc. . |
| Jackman (digital transformation consultancy) | Executive Board Advisor | Current (as of appointment) | Advises on digital transformation and growth strategy . |
Board Governance
- Committee memberships for Jason Lobel have not been disclosed in filings to date . The company’s standing committees are Audit, Compensation, and Nominating & Governance, which are chaired and composed entirely of independent directors per the latest annual proxy prior to his appointment .
- Following Director Michael Pruitt’s resignation on September 12, 2025, the Board stated it would fill Pruitt’s Audit and Compensation Committee roles with existing directors; specific assignments were not named in the 8-K .
- Independence and governance policies: the Board historically determined its directors to be independent under Nasdaq rules, and committees are fully independent . The company maintains a Code of Business Ethics and Conduct, discourages speculative/hedging transactions by insiders, and requires pre-clearance for trades, with quarterly blackout periods and Section 16 reporting within two business days .
- Attendance: 2023 board meetings totaled nine, with all directors attending; 2022 saw fourteen meetings with full attendance, but these precede Lobel’s tenure .
Fixed Compensation
Jason Lobel’s director compensation has not yet been disclosed in filings. For context, the 2023 non‑employee director compensation structure for sitting directors was as follows :
| Component | Amount/Structure | Notes |
|---|---|---|
| Quarterly cash fees | $11,250 per director per quarter | Total annual cash fees $45,000 per director . |
| Equity (RSUs) | 3,333 RSUs per director with immediate vesting; grant-date fair value $14,300 | RSUs granted; no options to directors in 2023 . |
Note: These figures applied to directors serving in 2023 (Evans, Pruitt, Sucoff). Lobel joined in 2025 and his specific compensation terms are not disclosed in the available filings .
Performance Compensation
- No performance-based equity (PSUs) or option awards were disclosed for non-employee directors in 2023; RSUs vested immediately and were service-based .
- No company-defined performance metrics (e.g., revenue, EBITDA, TSR) tied to director compensation are disclosed in the available filings for 2023–2025 .
Other Directorships & Interlocks
| Company | Listing | Role | Possible Interlocks/Conflicts |
|---|---|---|---|
| None disclosed (public company boards) | — | — | No public company directorships disclosed for Lobel; advisory role at Jackman and CEO role at GenomicMD noted . |
| GenomicMD (private) | — | CEO & Co-Founder | Company disclosed no Item 404(a) related-party transactions or family relationships at appointment . |
Expertise & Qualifications
- AI/ML and data analytics leadership (SwiftIQ; PDI Software initiatives) .
- Precision health diagnostics (GenomicMD CEO; genomic risk/early detection domain) .
- Investment banking experience (Duff & Phelps/Kroll) .
- Education: BBA in Finance, Investment and Banking, University of Wisconsin–Madison .
Equity Ownership
- Individual beneficial ownership for Jason Lobel is not disclosed in the June 2025 appointment 8‑K , and he does not appear in the security ownership table of the February 11, 2025 special proxy (record date January 27, 2025), which predates his appointment .
- No Form 3/4 holdings are presented in the available filings for Lobel; the company’s insider trading policy requires pre-clearance and Section 16 filings for directors .
Governance Assessment
- Strengths:
- No family relationships or related‑party transactions requiring Item 404(a) disclosure at appointment, supporting independence and reduced conflict risk .
- Board committees historically fully independent; formal Code of Ethics, clawback policy, and strict insider trading controls (blackouts, pre‑clearance, discouragement of hedging) bolster governance rigor .
- Watch items / potential red flags:
- Committee assignments and chair roles for Lobel are not yet disclosed; clarity on Audit/Compensation/Nominating placements will be important for evaluating board effectiveness post-2025 changes .
- Ongoing capital structure actions (e.g., Series G anti-dilution mechanics, equity line) and reverse split proposals increase dilution and governance sensitivity, warranting monitoring of director oversight and investor alignment, although these are corporate actions rather than Lobel-specific .
Overall: Lobel brings relevant healthcare data and AI/analytics expertise with prior transactional background, and no disclosed conflicts at appointment. Investors should seek forthcoming proxy disclosures for his committee roles, meeting attendance, and compensation to complete alignment and oversight evaluation .